Drugs / ISIS 325568
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00519727 | Aug 2007 → Apr 2008 | type 2 diabetes mellitus | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2007-10-02 | Ionis Pharmaceuticals | Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568 ionis.com ↗ |
| 2007-09-04 | Ionis Pharmaceuticals | Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes ionis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS 325568 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00519727 ↗ |
| Route | Subcutaneous | “single subcutaneous injection” NCT00519727 ↗ |